



Express Mail No.: EV 335 857 945 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Wilde et al.

Confirmation No.: 8259

Serial No.: 10/625,059

Group Art Unit: 1614

Filed: July 22, 2003

Examiner: To Be Assigned

For:

NUCLEOSIDE COMPOUNDS AND THEIR USE FOR TREATING CANCER AND DISEASES ASSOCIATED WITH SOMATIC MUTATIONS

Attorney Docket No.: 10589-015-999

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97 & §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent and Trademark Office of all references coming to the attention of Applicants or their attorneys which are or may be related to patentability of the claimed invention, Applicants hereby invite the Examiner's attention to references **A01** to **A06**, **B01** to **B04**, and **C01** to **C24**, which are listed on the accompanying revised PTO Form 1449.

A copy of references **A01** to **A06**, **B01** to **B04**, and **C01** to **C24** is submitted herewith. Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.



Identification of the listed references is not to be construed an admission by Applicants or their attorneys that such references are available as "prior art" against the subject application.

Pursuant to 37 C.F.R. § 1.97(b) because this Information Disclosure Statement is being filed before the mailing of a first Office action on the merits, it is estimated that no fee is due. However, if a fee is deemed to be due, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Date November 26, 2003

Respectfully submitted,

By: Anthony M. Insogna, Reg. No. 35,203
Michael J. Bluman, Reg. No. 47,458 35,203
Anthony M. Insogna (Reg. No.)
PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Express Mail No.: EV 335 857 945 US

Sheet 1 of 2

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO.	APPLICATION NO
	10589-015-999	10/625,059
	APPLICANT	
	Wilde, et al.	
	FILING DATE	GROUP
	July 22, 2003	1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	6,184,382	2/6/01	Salazar et al.			
	A02	6,043,228	3/28/00	McMurry et al.			
	A03	5,880,284	3/9/99	Himmelsbach et al.			
	A04	5,780,492	7/14/98	Dinsmore et al.			
	A05	5,041,542	8/20/91	Robins et al.			
	A06	3,946,033	3/23/76	Iwata et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
	B01	WO 00/24707	5/4/00	PCT					
	B02	WO 97/45400	12/4/97	PCT					
	B03	WO 96/11930	4/25/96	PCT					
	B04	EP 0 612 741 A1	2/21/94	EPO					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Barton-Davis et al., 1999, "Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice," <i>J. Clin. Invest.</i> 104(4):375-381
C02	Baxter et al., 1991, "Synthesis and Biological Activity of Carbocyclic Clitocine," <i>Nucleosides & Nucleotides</i> 10(1-3):393-396
C03	Bedwell et al., 1997, "Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line," <i>Nat Med.</i> 3(11):1280-4
C04	Burgdorf et al., 2002, "Synthesis, stability, and conformation of the formamidopyrimidine G DNA Lesion," <i>Chem. Eur. J.</i> 8(1):293-301
C05	Espie et al., 1990, "Synthesis of a Nitro Group Containing Ribonucleoside Related to Guanosine," <i>Tetrahedron Letters</i> 31(10):1423-1426
C06	Franchetti et al., 1995, "Acyclic Nucleotides Related to Clitocin: Synthesis and Anti-HIV Activity," <i>Nucleosides & Nucleotides</i> 14(3-5):607-610
C07	Franchetti et al., 1991, "Synthesis Of 3-Deazaclitocine [2-Amino-3-Nitro-4-(β -D-Ribofuranosylamino)Pyridine] As Cytotoxic Agent," <i>Nucleosides & Nucleotides</i> 10(1-3):543-545
C08	Ghose et al., 1990, "Structural Studies Of The Novel Antitumor Agents 4-Amino-8-(β -D-Ribofuranosylamino)Pyrimido[5,4- <i>d</i>]Pyrimidines And Their A-Anomers Using X-Ray, 1 H NMR, And Theoretical Methods," <i>J. Am. Chem. Soc.</i> 112:3622-3628
C09	Ghose et al., 1989, "Structural Mimicry Of Adenosine By The Antitumor Agents 4-Methoxy- And 4-Amino-8-(β -D-Ribofuranosylamino)Pyrimido-[5,4- <i>d</i>]Pyrimidine As Viewed By A Molecular Modeling Method," <i>PNAS</i> 86:8242-8246
C10	Grem et al., 1994, "Cytotoxicity and metabolism of 4-Methoxy-8-(β -D-Ribofuranosylamino)Pyrimido[5,4- <i>d</i>]Pyrimidine in HCT 116 Colon Cancer Cells," <i>Biochem. Pharmacol.</i> 48(11):2117-2126
C11	Hollstein et al., 1994, "Database of p53 gene somatic mutations in human tumors and cell lines," <i>Nucleic Acids Res.</i> 22(17):3551-3555
C12	Howard et al., 1996, "Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations," <i>Nat Med.</i> 2(4):467-469
C13	Kamikawa et al., 1988, <i>J. Chem. Soc. Chem. Comm.</i> 195

C14	Koshland, D., 1993, "Molecule of the year," <i>Science</i> 262(5142):1953
C15	Kubo et al., 1986, "Clitocine, a New Insecticidal Nucleoside from the Mushroom <i>Clitocybe inversa</i> ," <i>Tetrahedron Letters</i> 27(36):4277-4280
C16	Lee, 2001, "Clitocin Analogs to Inhibit Adenosine Kinase," <i>Bioorg. Med. Chem. Lett.</i> , 11:2419
C17	Lee et al., 2001, "Synthesis and Biological Evaluation of Clitocine Analogues as Adenosine Kinase Inhibitors," <i>Bioorg. & Med. Chem. Letters</i> 11:2419-2422
C18	Mabry et al., 1994, "Synthesis Of 4-Amino-8-(2,2-Difluoro-2-Deoxy- β -D-Ribo Furanosyl Amino)Pyrimido[5,4-D]Pyrimidine (DFARPP). Stability And Cellular Cytotoxicity," <i>Nucleosides and Nucleotides</i> 13(5):1125-1133
C19	Moss et al., 1988, "Synthesis, Intramolecular Hydrogen Bonding, And Biochemical Studies Of Clitocine, A Naturally Occurring Exocyclic Amino Nucleoside," <i>J. Med. Chem.</i> 31:786-790
C20	Nogueras et al., 1994, "Selective Synthesis of 6-Ribo- (and Xylo) Pyrano and Furano Aminopyrimidines. Anticancer and Anti-AIDS Activities," <i>Nucleosides & Nucleotides</i> 13(1-3):447-457
C21	Palmer et al., 1990, "Synthesis of Carbocyclic Clitocine," <i>Tetrahedron Letters</i> 31(2):279-282
C22	Sleat et al., 2001, "Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis," <i>Eur. J. Paediatr. Neurol.</i> 5 Suppl A:57-62
C23	Vincze et al., 1972, "Reaction of Diethyl Pyrocarbonate with Nucleic Acid Components. Bases and Nucleosides Derived from Guanine, Cytosine, and Uracil," <i>J. Am. Chem. Soc.</i> 95(8):2677-2682
C24	Zambetti et al., 1993, "A comparison of the biological activities of wild-type and mutant p53," <i>FASEB J.</i> 7(10):855-865

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

